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BASFIAbstract Aim of the work: The aim of this work was to assess the bone mineral density (BMD) in
Ankylosing Spondylitis (AS) patients and to investigate its relation with clinical and laboratory
parameters, imaging of sacroiliac joints, disease activity and physical function.
Patients and methods: 44 patients were recruited from the Rheumatology outpatient clinic of the
Kasr El-Aini Hospital, their mean age was 33 ± 8.7 years. Twenty age and sex matched subjects
were included as controls. Dual energy X-ray absorptiometry (DEXA) was performed for the
patients and control. Disease activity and physical function were assessed using the Bath AS
Disease Activity Index (BASDAI) and Bath AS Functional Index (BASFI), respectively.
Results: The T-scores of the spine, hip and forearm were lower in patients compared to controls.
Low BMD was more found among patients with chronic sacroiliitis. There were signiﬁcant negative
correlations between chin to chest and occiput to wall distance and BMD at the hip and forearm
(both p< 0.05). The BMD at the spine showed a signiﬁcant correlation with the BASDAI
(p= 0.008) and BASFI (p= 0.03). There was no correlation between BMD at any site and
patients’ age, disease duration, inﬂammatory back pain duration, modiﬁed Scho¨ber’s test, ﬁnger-
to-ﬂoor test and laboratory parameters.
Conclusion: The BMD was remarkably decreased at all measurement sites in AS patients. The
BMD at the spine signiﬁcantly negatively correlated with the disease activity and physical function.
Bone loss in AS can be explained partly by the role of inﬂammatory mediators and partly as a con-
sequence of reduced physical activity.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Ankylosing Spondylitis (AS) is a chronic inﬂammatory rheu-
matic disease, mainly affecting the sacroiliac joints, vertebrae
and intervertebral discs, leading to syndesmophyte formation
and impaired back mobility [1].
In AS two enhanced but opposite bone remodelling pro-
cesses are taking place in close vicinity within the spine which
are pathologic new bone formation in the cortical zone of the
vertebrae, the zygapophyseal joints, and the ligamentous appa-
ratus and excessive loss of trabecular bone in the centre of the
vertebral body leads to osteoporosis [2]. An increased preva-
lence of osteoporosis and signiﬁcantly lower bone mineral den-
sity (BMD) in AS patients compared with sex and age matched
controls have been demonstrated [3,4]. Measurement of bone
mass is useful in diagnosing osteoporosis commonly observed
in the lumbar spine and the femoral neck but not in the appen-
dicular skeleton. Osteoporosis is seen early in the disease
whereas increased bone mass is observed later or due to syn-
desmophyte formation. Osteoporosis in AS is probably a
multi-factorial condition. Contributing factors are spine
immobility secondary to ankylosis, inﬂammatory cytokines
which enhance bone resorption, prolonged use of nonsteroidal
antiinﬂammatory drugs (NSAIDs) and a deﬁcit in sex hor-
mone secretion [3,5]. Furthermore, there is no alteration in
calcium or phosphorus metabolism in AS [6]. The only evi-
dence-based recommendation is that optimal control of disease
activity in AS prevents bone loss. A beneﬁcial effect of inﬂix-
imab therapy on bone turnover markers and BMD in AS
has been shown; bisphosphonates may be useful in managing
osteoporosis in AS [7].
Several surveys have reported the prevalence of vertebral
fractures in AS patients [3,8,9]. These studies indicate that verte-
bral fractures are a regular ﬁnding in patients with AS but their
prevalence is highly variable. These differences are at least in
part a reﬂection of differences in recruitment methods (e.g. con-
secutive patients, selected patients based on disease activity or
occiput-to-wall distance, sex distribution, age and clinical versus
systematic morphometric fractures) and the deﬁnition of verte-
bral fractures. Adetailed description of vertebral fractures inAS
appears to be derived from the study by Cooper and colleagues
[10]. This retrospective population-based study on clinical frac-
tures reported an increased odds ratio (OR) of 7.7 (95% conﬁ-
dence interval 4.3–12.6) for clinical vertebral fractures. The
cumulative incidence of clinical vertebral fractures was higher
in men (OR 10.7 versus 4.2 in women) and increased during
the ﬁrst 5 years of the disease, peaking at 17%, 20–30 years after
diagnosis. Of interest, the cumulative incidence of nonvertebral
fractures was similar to the control population. As this popula-
tion study involved clinical vertebral fractures, it still remains
unclear what is the exact prevalence and incidence of morpho-
metric vertebral fractures in AS.
The aim of this work was to assess the bone mineral density
(BMD) in Ankylosing Spondylitis (AS) patients and to investi-
gate its relation with clinical and laboratory parameters, imag-
ing of sacroiliac joints, disease activity and physical function.2. Patients and methods
In this cross-sectional study, 44 Ankylosing Spondylitis (AS)
patients were recruited from the Rheumatology outpatientsclinic Kasr El Aini Hospital, Faculty of Medicine, Cairo Uni-
versity. Patients were diagnosed according to the modiﬁed
New York criteria [11]. Patients with any condition or treat-
ment that might have affected bone metabolism (malabsorp-
tion, chronic renal and liver diseases, thyroid diseases,
alcoholism, corticosteroids, anticonvulsants) and patients with
other forms of spondyloarthropathies were excluded. The con-
trol group consisted of 20 age- and sex-matched healthy sub-
jects without a history of inﬂammatory rheumatic disease,
conditions or medication responsible for bone loss. The study
was approved by the local ethics committee and was per-
formed in accordance with ethical standards of the 1964 Dec-
laration of Helsinki. Patients gave informed consent to be
included in the study.
Demographic and clinical variables were recorded from all
patients including age, disease duration, age of disease onset,
peripheral arthritis, axial joints involved and uveitis.
Functional status and measures of disease activity and
severity were obtained using established methods. Functional
ability was assessed by Bath Ankylosing Spondylitis Func-
tional Index (BASFI) [12]. BASFI is a set of 10 questions
designed to determine the degree of functional limitation in
AS. It is a self-assessment tool where a 100 mm horizontal
visual analogue scale (VAS) is used to answer the questions
that reﬂect the ability to perform speciﬁc tasks. The mean of
the ten scales gives the BASFI score, value between 0 and 100.
Disease activity was measured by the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [13]. The BAS-
DAI is also a self-assessment tool that evaluates a range of
symptoms. Like the BASFI, the BASDAI consists of
100 mm horizontal VAS used to answer 6 questions pertaining
to the 5 major symptoms of AS: fatigue, spinal pain, pain and
swelling in other joints, discomfort with peripheral entheses
and severity and duration of morning stiffness. To give each
symptom equal weighting, the mean of two scores relating to
morning stiffness is taken. The resulting score is then divided
by 5 to give the ﬁnal BASDAI score (0–100).
Spinemobility was assessed using themodiﬁed Scho¨ber’s test
[14]. We have also recorded the patients’ medication history
including intermittent or continuous use of NSAIDs, disease-
modifying drugs (DMARDs) and tumour necrosis factor-alpha
(TNFa) blockers (Inﬂiximab, Etanercept and Adalimumab).
Sacroiliac and lumbosacral MRI were examined in order to
grade the sacroiliitis that was deﬁned by signal characteristic
of the joint space, presence of bone marrow oedema or erosion
adjacent to the joint (according to New York criteria) and to
assess the syndesmophytes [15]. Chronic sacroiliitis was deﬁned
by low signal intensity on T1 and T2 weighted images, subchon-
dral sclerosis, joint space narrowing and bone bridging. While,
the presence of erosions as high signal intensity on T2 image,
subchondral oedema and enhancement within or adjacent to
the sacroiliac joint were considered markers of active inﬂamma-
tory lesion. Inﬂammatory activity was also measured by eryth-
rocyte sedimentation rate (ESR) and C-reactive protein (CRP)
(by ELISA, normal values <5 mg/L).
Bone mineral density (BMD) was measured at the postero-
anterior (PA) lumbar spine (L2–L4), forearm and hip by
means of dual energy X-ray absorptiometry (DEXA). Results
were expressed as T-score (standard deviation from peak adult
BMD). According to the WHO criteria, osteopenia was
deﬁned as T-score between 1 and 2.5 and osteoporosis as
a T-score below 2.5 [16].
Table 1 Clinical and radiographic features of the Ankylosing
spondylitis (AS) patients (n= 44).
Variables AS patients (n= 44)
Range Mean ± SD
Age (years) 19–57 32.97 ± 8.7
Age of onset (years) 18–42 29.60 ± 6.7
Disease duration (years) 1–27 5.6 ± 7.5
MS duration (minutes) 30–180 100.9 ± 50.9
IBP duration (years) 1–27 5.7 ± 7.5
Modiﬁed Sco¨ber test (cm) 3–6.7 4.5 ± 0.8
Finger-to-ﬂoor test (cm) 25.5–56 40.1 ± 8.9
Chin-to-chest (cm) 0–0.5 0.05 ± 0.13
Occiput-to-wall (cm) 0–1 0.21 ± 0.33
Chest expansion (cm) 2–6 4.30 ± 1.05
BASDAI 1.8–8.8 5.70 ± 1.79
BASFAI 2.4–8 5.80 ± 1.42
MRI of sacroiliac: n (%)
Normal 6 (13.6)
Acute sacroiliitis 8 (18.2)
Chronic sacroiliitis 30 (68.2)
AS: ankylosing spondylitis, MS: morning stiffness, IBP: inﬂam-
matory back pain, BASDAI: bath ankylosing spondylitis disease
activity index, BASFI: bath ankylosing spondylitis functional
index, MRI: magnetic resonance imaging.
Table 2 The laboratory and osteodensiometric features in AS
patients and controls.
Variables AS patients Controls p value
(n= 44) (n= 20)
DEXA (T score)
Spine 1.12 ± 1.5 0.41 ± 0.57 0.007
Hip 1.27 ± 0.95 0.46 ± 0.65 0.001
Forearm 0.67 ± 0.93 0.06 ± 0.69 0.008
ESR (mm/1st h) 42.68 ± 29.78 13 ± 8.1 0.001
CRP (mg/dl) 50.30 ± 57.66 4.8 ± 4.1 0.001
DEXA: dual energy X-ray absorptiometry, ESR: erythrocyte
sedimentation rate, CRP: C reactive proteins.
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was used for statistical analysis. Results were expressed as
mean (standard deviation), or number (percentage). Student’s
t-test was used to compare continuous variables between AS
patients and controls, and between subgroups of AS patients.
The chi-square test for the categorical variables was performed
when appropriate. The correlations between variables were
presented as the Spearman’s correlation coefﬁcient (rho). A
multivariate logistic regression analysis model was performed
to detect any predictive risk factors for the low BMD. The
level of statistical signiﬁcance was <0.05 (2-tailed).
3. Results
Our study included 44 patients (42 males and 2 females), their
demographic, clinical, and laboratory characteristics of the
patient group are listed in Tables 1 and 2. Ninety-seven percent
of the patients were receiving intermittent or continuous treat-
ment with NSAIDs and 80% of the patients were also treated
with at least one disease-modifying drug (sulphasalazine,
methotrexate and leﬂunomide). Demographic, clinical and
radiographic data of the patients are shown in Table 1.
All AS patients (100%) had inﬂammatory back pain, 20
(45%) had peripheral arthritis, 4 (9%) had unilateral and/or
bilateral uveitis and 36 (82%) were HLA-B27 positive. None
of the patients had syndesmophytes The BMI was comparable
between patients and controls (p= 0.4) and there were no gen-
der differences of value. The laboratory and osteodensiometric
variables in patients and controls are shown in Table 2.
The T-scores of the spine, hip and forearm were lower in
AS patients compared to controls. Signiﬁcantly more AS
patients were osteopenic at the hip (p= 0.001), at the lumbar
spine (p= 0.007), and the forearm (p= 0.008) (Table 2).
According to the WHO classiﬁcation for osteoporosis for the
lumbar spine, 8 (19%) AS patients were osteoporotic, 22
(50%) were osteopenic and 14 (31%) were normal (controls;
0%, 10%, 90% respectively). At the hip, 32 (73%) AS patients
were osteopenic, 12 (27%) were normal and none of them was
osteoporotic (controls; 20%, 80% respectively). While, at the
forearm, 6 (14%) AS patients were osteopenic, 4 were osteopo-
rotic and 34 (77%) normal (controls; 10%, 90% respectively)
(Table 3).
Low BMD was more found among the patients with
chronic sacroiliitis. Out of 30 patients with chronic sacroiliitis,
16 were osteopenic at the lumbar spine and 6 were osteopo-
rotic. While, from 8 patients with acute sacroiliitis; 4 were oste-
openic and 2 were osteoporotic. Signiﬁcant association was
found between the chronic sacroiliitis and osteopenia in the
hip and lumbar spine (contingency coefﬁcient, 0.72,
p= 0.001, 0.75, p= 0.001 respectively). The classiﬁcation of
patients was done according to their MRI ﬁndings at the
Sacroiliac joints and DEXA values at the lumbar spine
(Table 4).
There were signiﬁcant negative correlations between chin to
chest & occiput to wall distance and BMD at the hip & fore-
arm (both p< 0.05). The BMD at the spine showed a signiﬁ-
cant negative correlation with each of BASDAI (p= 0.008) &
BASFAI (p= 0.03). There was no correlation between BMD
at any site and patient’s age, disease duration, inﬂammatory
back pain duration, modiﬁed Scho¨ber test, ﬁnger-to-ﬂoor test
and laboratory parameters (ESR, CRP) (p> 0.05). (Table 5).Signiﬁcant parameters in univariate analysis were tested in
multivariate logistic regression model and showed no signiﬁ-
cant association between low BMD and each of the following;
inﬂammatory parameters in MRI of the sacroiliac joint (OR:
0.01, p= 0.9), BASDAI (OR: 0.9, P= 0.8), BASFI (OR:
0.8, P= 0.4).
4. Discussion
The results of this cross-sectional study exploring the BMD at
different measurement sites (spine, hip & forearm) and the
incidence of reduced BMD, revealed that patients with AS
had lower bone mass than healthy age- and sex-matched con-
trols. Further analysis demonstrated that BMD at the spine
was correlated with disease activity and function variables
(e.g. BASDAI & BASFI) that reﬂected the cumulative damage
of AS. In contrast, no correlation was found between BMD at
any site and patient’s age or disease duration.
Table 4 Spine DEXA in AS patients according to the MRI
ﬁndings at the sacroiliac joint.
MRI Lumbar spine DEXA
Osteopenic Osteoporotic
Acute sacroiliitis 4 2
Chronic sacroiliitis 16 6
MRI: magnetic resonance imaging, DEXA: dual energy X-ray
absorptiometry.
Table 5 Pearson correlation coefﬁcients for BMD value
versus other parameters.
Variables Lumbar spine BMD Hip BMD Forearm BMD
*Age 0.95 0.14 0.41
*Dis. duration 0.92 0.64 0.26
*MS duration 0.45 0.76 0.78
*IBP duration 0.93 0.64 0.26
*Schober test 0.85 0.19 0.45
*Finger to ﬂoor test 0.26 0.93 0.54
*Occiput to wall 0.82 0.007* 0.001*
*Chin to chest 0.07 0.01* 0.001*
*BASDAI 0.008* 0.06 0.01*
*BASFAI 0.03* 0.77 0.67
*ESR 0.55 0.87 0.24
*CRP 0.29 0.7 0.21
BMD: bone mineral density, BASDAI: bath ankylosing spondylitis
disease activity index, BASFAI: bath ankylosing spondylitis func-
tional index, ESR: erythrocyte sedimentation rate, CRP: C reactive
proteins.
* Statistically signiﬁcant correlation (p< 0.05).
Table 3 Bone mineral density in AS patients according to the
WHO classiﬁcation.
Site N (%) DEXA
Normal Osteopenic Osteoporotic
Spine 14 (31) 22 (50) 8 (18)
Hip 12 (27) 32 (73) 0 (0)
Forearm 34 (77) 6 (14) 4 (9)
DEXA: dual energy X-ray absorptiometry.
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lower BMD in AS patients [3,17,18]. In contrast, lumbar spine
BMD values were similar or even increased in AS patients with
advanced disease, as compared to controls. It was suggested
that in late AS, the presence of syndesmophytes could falsely
elevate the spine BMD values [3,10]. In contrast to the afore-
mentioned studies, we did not ﬁnd a signiﬁcant increase in
bone mass at the lumbar spine. This might be explained by
the heterogeneity of the studied population, since we have
included AS patients in all stages of the disease, and all of
the patients did not have syndesmophytes. In another studyon a cohort of 103 patients with AS, Karberg et al. [19]
reported that bone loss was more frequently detected in AS
patients with syndesmophytes, suggesting that bone growth
and bone loss occurred in parallel. Their conclusion was that
‘‘the method of bone density measurement is critical and
should be different depending on disease duration’’. It was
established that DEXA at the femoral neck was the most sen-
sitive method for evaluating osteoporosis in AS, even in
patients without syndesmophytes. In contrast to their ﬁnding,
we did not ﬁnd a signiﬁcant relation between the BMD any site
and disease duration.
The WHO criteria for the Osteoporosis diagnosis have
been validated for postmenopausal white women, while AS
is a systemic disease mainly affecting male subjects. However,
fracture risk is associated with a T score less than 2.5 SD
in both sexes, and therefore it is reasonable to accept this
classiﬁcation in the absence of validated values in AS
patients [16]. In our study, we found an increased prevalence
of osteoporosis at the lumbar spine (18%) and osteopenia in
50% of the patients. These results were consistent with the
reported prevalence of osteoporosis in AS varying from
18.7% to 62% [20]. We could not report the sex difference
in our patients because most of them were males (42 males
and only 2 females). The present study demonstrated a con-
sistent, statistically signiﬁcant BMD decrease at all measure-
ment sites in patients with AS, as compared to age-matched
healthy controls. In contrast, Franck et al. [21], examining
190 males with AS, had demonstrated a signiﬁcant BMD
reduction only in the hip.
Also we found that BMD at the spine was correlated with
parameters reﬂecting the disease activity and function (BAS-
DAI, BASFI); and the BMD at the hip correlated with param-
eters reﬂecting the cumulative damage of AS (occiput-to-wall
and chin-to-chest tests). In contrast to the study of Muntean
et al. [22], who found a signiﬁcant correlation between the
BMD at any site and disease activity parameters, while they
found signiﬁcant correlation between the BMD at the hip
and the Scho¨ber’s test. The results suggested that bone loss
in AS may involve different mechanisms at different stages
of the disease.
By the Multivariate logistic regression analysis, we could
not specify certain risk factor associated with low BMD in
AS patients. On the other hand, Briot et al. [23,24], reported
that the main risk factor associated with low BMD in AS
patients was the presence of bone marrow oedema (inﬂamma-
tory lesions) on MRI. The difference could be explained by the
predominance of chronic sacroiliitis among our patients.
In conclusion, the BMD was remarkably decreased at all
measurement sites in AS patients. The BMD at the spine sig-
niﬁcantly negatively correlated with the disease activity and
physical function. Bone loss in AS, can be explained partly
by the role of inﬂammatory mediators and partly as a conse-
quence of the reduced physical activity. Larger scale longitudi-
nal studies are recommended in future work to conﬁrm our
ﬁndings and to take into consideration the reduced bone den-
sity when treating AS patients.Conﬂict of interest
No conﬂict of interest is declared by the authors.
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